GlassScriptPhysician profile
Linda L Davis
NPI 1659301422
$4,724.95
in general payments reported to CMS, 2019-2025
33 companies · $304 in 2025
The $304 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $720 · 2022: $1,004 · 2023: $1,123 · 2024: $1,574 · 2025: $304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,901 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,900.87 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $732.70 | 2021-2024 | Xtandi, Myrbetriq |
| Abbvie INC. | $523.19 | 2021-2025 | |
| Janssen Biotech, INC. | $390.25 | 2021-2025 | Erleada, Akeega, Rybrevant |
| Myriad Genetic Laboratories, INC. | $370.06 | 2021-2024 | Myrisk |
| Sumitomo Pharma America, INC. | $298.70 | 2023-2024 | Gemtesa, Orgovyx |
| Coloplast Corp | $282.68 | 2021-2025 | |
| 180 Medical, INC. | $269.65 | 2021-2025 | |
| Urovant Sciences INC | $241.04 | 2021-2022 | |
| Urogen Pharma, INC. | $189.52 | 2023-2024 | Jelmyto |
| Merck Sharp & Dohme LLC | $187.61 | 2021-2024 | Keytruda, Lynparza, Welireg |
| Antares Pharma, INC. | $176.10 | 2021-2022 | |
| Pfizer INC. | $153.24 | 2021-2024 | |
| Ferring Pharmaceuticals INC. | $115.83 | 2024 | Adstiladrin |
| Endo Pharmaceuticals INC. | $106.88 | 2022-2024 | Aveed, Xiaflex |
| Boston Scientific Corporation | $85.74 | 2023-2024 | Rezum Generator, Ams 700 Cxr Rte Kit, Spaceoar Vue System - 10ml |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar, INC. | $62.51 | 2024 | |
| Axonics, INC. | $57.13 | 2023-2024 | Axonics, Bulkamid |
| Procept Biorobotics Corporation | $51.75 | 2023-2024 | Aquabeam Robotic System, Aquabeam System |
| Endo USA, INC. | $47.23 | 2024 | Aveed, Xiaflex |
| Alnylam Pharmaceuticals INC. | $38.57 | 2023 | Givlaari |
| Hollister Incorporated | $36.50 | 2021-2022 | |
| Dendreon Pharmaceuticals LLC | $35.01 | 2021-2022 | |
| Angiodynamics, INC. | $32.35 | 2022 | |
| Integra Lifesciences Corporation | $32.03 | 2023 | Integra, Omnigraft, Integra Dermal Regeneration Template |
| Olympus America INC. | $31.98 | 2023-2024 | Itind System |
| Myovant Sciences INC. | $31.71 | 2021-2022 | |
| Allergan, INC. | $30.83 | 2021 | |
| Tolmar Pharmaceuticals, INC. | $29.09 | 2021 | |
| Blue Earth Diagnostics | $20.79 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $20.08 | 2023 | Seglentis |
| Astrazeneca Pharmaceuticals LP | $15.94 | 2023 | Lynparza |
| Rochester Medical Corporation | $14.78 | 2022 | |
| Monaghan Medical Corporation | $13.48 | 2023 | Aeroeclipse |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Linda Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.